Kura Oncology up as leukemia drug shows strong survival in early- to mid-stage trial
11/06/2026 14:04
BUZZ-Kura Oncology up as leukemia drug shows strong survival in early- to mid-stage trial ** Shares of biotech firm Kura Oncology KURA.O rise around 3% to $8.99 in premarket trading
** Experimental drug ziftomenib helped treat acute myeloid leukemia, a fast-growing blood cancer affecting the bone marrow, in an early- to mid-stage trial, co says
** Most patients had no measurable disease and responses lasted over time, co says
** Adds, safety profile was manageable with no new concerns, with data supporting late-stage study KOMET-017 in newly diagnosed patients
** As of last close, stock down around 16% YTD
(Reporting by Sahil Pandey in Bengaluru)